Fred E. Cohen - Aug 6, 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Director
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Aug 6, 2024
Transactions value $
$0
Form type
4
Date filed
8/8/2024, 09:11 AM
Previous filing
Jun 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right ot buy) Award $0 +10K $0.00 10K Aug 6, 2024 Ordinary Shares 10K $15.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.